Literature DB >> 10511808

[Multicenter evaluation of broth microdilution test, BrothMIC MTB, to determine minimum inhibitory concentrations (MICs) of antimicrobial agents for Mycobacterium tuberculosis--evaluation of interlaboratory precision and interpretive compatibility with agar proportion method].

N Yamane1, S Ichiyama, S Kawahara, Y Iinuma, H Saitoh, M Shimojima, H Udagawa, I Nakasone.   

Abstract

A newly developed microdilution antimycobacterial susceptibility test, BrothMIC MTB (Kyokuto Pharmaceutical Industrial Co., Ltd., Tokyo, Japan) to determine minimum inhibitory concentrations (MICs) was evaluated at multisites. The test method utilizes air-dried microplates containing serially diluted antimicrobial agents and the modified Middlebrook 7H9 broth. The eight antimycobacterial agents tested were rifampicin, isoniazid, ethambutol, streptomycin, kanamycin, levofloxacin, sparfloxacin and ciprofloxacin. The test plates were reconstituted by inoculation of 0.2 ml of cell suspensions (6 x 10(5) cells/ml) and were incubated at 36 degrees C in 5% to 10% CO2. The growth endpoints were visually read after 7-day and 10-day incubations. The reproducibility was evaluated with the four reference strains of Mycobacterium tuberculosis, and were compared with the agar proportion method described in the National Committee for Clinical Laboratory Standards (NCCLS) M24-T. Of the 1,022 testings of the reference strains, 1,020 (99.8%) of the MICs read after 7-day incubation fell within 3 log2 dilutions. The growth endpoints read after 7-day and 10-day incubations gave equal MIC ranges for the respective agents. The results obtained by the BrothMIC MTB for 93 clinical isolates of M. tuberculosis compared well with those determined by the NCCLS method with 98% to 99% agreements, except for ethambutol. According to the comparative analysis with the agar proportion method, the interpretive MIC breakpoints to discriminate between the isolates susceptible and resistant against the respective agents were proposed. In conclusion, this newly developed microdilution test for M. tuberculosis is a practical, rapid, quantitative, nonradiometric alternative for the determination of MICs in clinical mycobacteriology laboratories.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10511808

Source DB:  PubMed          Journal:  Rinsho Byori        ISSN: 0047-1860


  5 in total

1.  In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis.

Authors:  Prakash M Jeena; William R Bishai; Jotam G Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-11-22       Impact factor: 5.191

Review 2.  An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.

Authors:  Jotam Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

3.  In vitro susceptibility of Mycobacterium tuberculosis isolates to an oral carbapenem alone or in combination with β-lactamase inhibitors.

Authors:  Yasuhiro Horita; Shinji Maeda; Yuko Kazumi; Norio Doi
Journal:  Antimicrob Agents Chemother       Date:  2014-09-15       Impact factor: 5.191

4.  Antitubercular activity of disulfiram, an antialcoholism drug, against multidrug- and extensively drug-resistant Mycobacterium tuberculosis isolates.

Authors:  Yasuhiro Horita; Takemasa Takii; Tetsuya Yagi; Kenji Ogawa; Nagatoshi Fujiwara; Emi Inagaki; Laurent Kremer; Yasuo Sato; Ryuji Kuroishi; Yoosa Lee; Toshiaki Makino; Hajime Mizukami; Tomohiro Hasegawa; Ryuji Yamamoto; Kikuo Onozaki
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

5.  New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability.

Authors:  Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.